Update - 22 January 2022
Our Innovation Centres remain operational and accessible, and provide a safe environment for our staff and customers. We continue to assess the risk of COVID-19 alongside the latest guidance from government. In the meantime our Innovation Centre remains COVID-19 Secure and fully open for business. Our detailed risk assessment can be found here.
About this event Come and hear the real-life story of start-up to exit from David Llewellyn, Managing Director and Co-Founder of Oxford-based biotech company, DJS Antibodies. Founded in 2014, DJS was acquired by AbbVie in October 2022 for $255m to access their lead IPF programme as well as revolutionary HEPTAD […]
Update – 11 August 2022
Our Innovation Centres remain operational and accessible, and provide a safe environment for our staff and customers. We continue to assess the risk of COVID-19 alongside the latest guidance from government. In the meantime our Innovation Centre remains COVID-19 Secure and fully open for business. Our detailed risk assessment can be found here.
